Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Liye Zhou(Dana-Farber Cancer Institute), Ravindra Uppaluri(Dana-Farber Cancer Institute), Rachel Riley(Rowan University), Ann Marie Egloff(Brigham and Women's Hospital), Shengqing Gu(Dana-Farber Cancer Institute), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Peter P. Du(Stanford University), James A. Lederer(Brigham and Women's Hospital), X. Shirley Liu(Harbin Medical University), Katie M. Campbell(University of California, Los Angeles), Jingxin Fu(Tongji University), Yasutaka Nakahori(Brigham and Women's Hospital), Fei Guo(Harbin Engineering University), Zexian Zeng(Peking University), Robert I. Haddad(Georgetown University), Paul Zolkind(Washington University in St. Louis), Yi Zhang(Case Western Reserve University), Fan Zhang(Brigham and Women's Hospital), Zhe Zhang(University Gastroenterology), Xiaoqing Wang(Luoyang Orthopedic-Traumatological Hospital of Henan Province), Obi L. Griffith(Washington University in St. Louis), Joshua Keegan, Xiaojing Ma(Hefei University of Technology)
Cited by 51
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
|Genome biology|2016|2.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k